Publications
-
Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line.
Parker JJ,
Jones JC, Strober S, Knox SJ.
Clin Immunol.
2013;
148
(1):
44-55
-
A systemic complete response of metastatic melanoma to local radiation and immunotherapy.
Hiniker SM,
Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ.
Transl Oncol.
2012;
5
(6):
404-7
-
Abscopal effect in a patient with melanoma.
Hiniker SM,
Chen DS, Knox SJ.
N Engl J Med.
2012;
366
(21):
2035; author reply 2035-6
-
Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.
Oronsky BT,
Scicinski JJ, Reid T, Knox S.
Transl Oncol.
2012;
5
(3):
133-40
-
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
Tian J,
Zhao H, Nolley R, Reese SW, Young SR, Li X, Peehl DM, Knox SJ.
Clin Cancer Res.
2012;
18
(12):
3366-76
-
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials.
Ning S,
Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ.
Cancer Res.
2012;
72
(10):
2600-8
-
Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.
Oronsky BT,
Knox SJ, Scicinski JJ.
Transl Oncol.
2012;
5
(2):
66-71
-
Mitigation of radiation-induced dermatitis by activation of aldehyde dehydrogenase 2 using topical alda-1 in mice.
Ning S,
Budas GR, Churchill EN, Chen CH, Knox SJ, Mochly-Rosen D.
Radiat Res.
2012;
178
(1):
69-74
-
The scarlet letter of alkylation: a mini review of selective alkylating agents.
Oronsky BT,
Reid T, Knox SJ, Scicinski JJ.
Transl Oncol.
2012;
5
(4):
226-9
-
Six degrees of separation: the oxygen effect in the development of radiosensitizers.
Oronsky BT,
Knox SJ, Scicinski J.
Transl Oncol.
2011;
4
(4):
189-98
-
131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma.
Iagaru A,
Mittra ES, Ganjoo K, Knox SJ, Goris ML.
Mol Imaging Biol.
2010;
12
(2):
198-203
-
Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats.
Ning S,
Tian J, Marshall DJ, Knox SJ.
Cancer Res.
2010;
70
(19):
7591-9
-
Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status.
Tian J,
Peehl DM, Zheng W, Knox SJ.
Cancer Lett.
2010;
298
(2):
231-7
-
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S,
Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, Lobuglio AF.
J Nucl Med.
2010;
51
(1):
150-7
-
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD,
Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R.
J Clin Oncol.
2010;
28
(28):
4324-32
-
Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry.
Tian J,
Peehl DM, Knox SJ.
Cancer Biother Radiopharm.
2010;
25
(4):
439-48
-
Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo.
Tian J,
Ning S, Knox SJ.
Int J Radiat Oncol Biol Phys.
2010;
78
(1):
230-6
-
Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.
Ning S,
Knox SJ, Harsh GR, Culler MD, Katznelson L.
Endocr Relat Cancer.
2009;
16
(3):
1045-55
-
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo.
Ning S,
Nemeth JA, Hanson RL, Forsythe K, Knox SJ.
Mol Cancer Ther.
2008;
7
(6):
1569-78
-
Risks to normal tissues from radionuclide therapy.
Meredith R,
Wessels B, Knox S.
Semin Nucl Med.
2008;
38
(5):
347-57
-
Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
Bhattacharyya RS,
Husbeck B, Feldman D, Knox SJ.
Int J Radiat Oncol Biol Phys.
2008;
72
(3):
935-40
-
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
Kim YH,
Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ.
Blood.
2007;
109
(11):
4655-62
-
Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients.
Sinclair AM,
Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG.
Cancer.
2007;
110
(3):
477-88
-
MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy?
Sgouros G,
Knox SJ, Joiner MC, Morgan WF, Kassis AI.
J Nucl Med.
2007;
48
(10):
1683-91
-
Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis.
Ning S,
Chen Z, Dirks A, Husbeck B, Hsu M, Bedogni B, O'Neill M, Powell MB, Knox SJ.
Radiat Res.
2007;
168
(1):
125-33
-
Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Meredith RF,
Knox SJ.
Int J Radiat Oncol Biol Phys.
2006;
66
(2 Suppl):
S15-22
-
Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation.
Patel DA,
Kochanski J, Suen AW, Fajardo LF, Hancock SL, Knox SJ.
Cancer.
2006;
106
(3):
718-25
-
Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action.
Husbeck B,
Bhattacharyya RS, Feldman D, Knox SJ.
Mol Cancer Ther.
2006;
5
(8):
2078-85
-
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma.
Ning S,
Knox SJ.
Int J Radiat Oncol Biol Phys.
2006;
65
(2):
493-8
-
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer.
Street HH,
Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ.
Cancer Biother Radiopharm.
2006;
21
(3):
243-56
-
Radiation sensitization with redox modulators: a promising approach.
Rosenberg A,
Knox S.
Int J Radiat Oncol Biol Phys.
2006;
64
(2):
343-54
-
Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells.
Husbeck B,
Nonn L, Peehl DM, Knox SJ.
Prostate.
2006;
66
(2):
218-25
-
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Bennett JM,
Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL.
Blood.
2005;
105
(12):
4576-82
-
Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia.
Ning S,
Hartley C, Molineux G, Knox SJ.
Cancer Res.
2005;
65
(1):
284-90
-
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Kaminski MS,
Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL.
J Clin Oncol.
2005;
23
(31):
7985-93
-
Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing.
Husbeck B,
Peehl DM, Knox SJ.
Free Radic Biol Med.
2005;
38
(1):
50-7
-
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI,
Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M.
J Clin Oncol.
2005;
23
(30):
7565-73
-
A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L,
Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ.
Int J Radiat Oncol Biol Phys.
2004;
58
(4):
1215-27
-
Dosimetry model for radioactivity localized to intestinal mucosa.
Fisher D,
Rajon D, Breitz H, Goris M, Bolch W, Knox S.
Cancer Biother Radiopharm.
2004;
19
(3):
293-307
-
Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors.
Maxim PG,
Carson JJ, Ning S, Knox SJ, Boyer AL, Hsu CP, Benaron DA, Walleczek J.
Radiat Res.
2004;
162
(2):
185-93
-
Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier.
Wartchow CA,
Alters SE, Garzone PD, Li L, Choi S, DeChene NE, Doede T, Huang L, Pease JS, Shen Z, Knox SJ, Cleland JL.
Pharm Res.
2004;
21
(10):
1880-5
-
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S,
Knox SJ.
Int J Radiat Oncol Biol Phys.
2004;
60
(1):
197-203
-
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Forero A,
Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF.
Blood.
2004;
104
(1):
227-36
-
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
Hernandez MC,
Knox SJ.
Int J Radiat Oncol Biol Phys.
2004;
59
(5):
1274-87
-
The radioisotope contributes significantly to the activity of radioimmunotherapy.
Davis TA,
Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ.
Clin Cancer Res.
2004;
10
(23):
7792-8
-
Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma.
Yuen AR,
Higgins JP, Baker R, Kamel OW, Warnke RA, Knox SJ.
Hum Pathol.
2003;
34
(4):
381-4
-
Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells.
Li L,
Steinauer KK, Dirks AJ, Husbeck B, Gibbs I, Knox SJ.
Radiat Res.
2003;
160
(6):
617-21
-
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
Hernandez MC,
Knox SJ.
Semin Oncol.
2003;
30
(6 Suppl 17):
6-10
-
Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line.
Armstrong JS,
Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, Peehl DM, Knox SJ.
Cell Death Differ.
2002;
9
(3):
252-63
-
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S,
Laird D, Cherrington JM, Knox SJ.
Radiat Res.
2002;
157
(1):
45-51
-
Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization.
Armstrong JS,
Steinauer KK, French J, Killoran PL, Walleczek J, Kochanski J, Knox SJ.
Exp Cell Res.
2001;
262
(2):
170-9
-
Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University.
Murtha AD,
Rupnow BA, Hansosn J, Knox SJ, Hoppe R.
Int J Radiat Oncol Biol Phys.
2001;
49
(1):
3-15
-
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Kaminski MS,
Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM.
J Clin Oncol.
2001;
19
(19):
3918-28
-
Radioimmunotherapy of B-cell NHL.
Meredith RF,
Knox SJ.
Curr Pharm Biotechnol.
2001;
2
(4):
327-39
-
Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW.
Armstrong JS,
Hornung B, Lecane P, Jones DP, Knox SJ.
Biochem Biophys Res Commun.
2001;
289
(5):
973-8
-
Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96365-induced apoptosis.
Williams SS,
French JN, Gilbert M, Rangaswami AA, Walleczek J, Knox SJ.
Cancer Res.
2000;
60
(16):
4358-61
-
Clinical radioimmunotherapy.
Knox SJ,
Meredith RF.
Semin Radiat Oncol.
2000;
10
(2):
73-93
-
Introduction
Knox SJ,
Semin Radiat Oncol.
2000;
10
(2):
71-2
-
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Vose JM,
Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS.
J Clin Oncol.
2000;
18
(6):
1316-23
-
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Knox SJ,
Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM.
Clin Cancer Res.
2000;
6
(2):
406-14
-
Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells.
Steinauer KK,
Gibbs I, Ning S, French JN, Armstrong J, Knox SJ.
Int J Radiat Oncol Biol Phys.
2000;
48
(2):
325-8
-
G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation.
Ning S,
Knox SJ.
Radiat Res.
1999;
151
(6):
659-69
-
Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB,
Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.
Cancer Biother Radiopharm.
1999;
14
(5):
381-95
-
Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system.
Ning S,
Yu N, Brown DM, Kanekal S, Knox SJ.
Radiother Oncol.
1999;
50
(2):
215-23
-
The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy.
Rupnow BA,
Knox SJ.
Apoptosis.
1999;
4
(2):
115-43
-
Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy.
Rupnow BA,
Murtha AD, Alarcon RM, Giaccia AJ, Knox SJ.
Cancer Res.
1998;
58
(9):
1779-84
-
Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo.
Ning S,
Shui C, Khan WB, Benson W, Lacey DL, Knox SJ.
Int J Radiat Oncol Biol Phys.
1998;
40
(1):
177-87
-
Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor.
Rupnow BA,
Murtha AD, Chen E, Knox SJ.
Cancer Lett.
1998;
127
(1-2):
211-9
-
p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts.
Rupnow BA,
Alarcon RM, Giaccia AJ, Knox SJ.
Cell Death Differ.
1998;
5
(2):
141-7
-
A prospective study of radiation therapy-associated thrombocytopenia.
Knox SJ,
Varghese A, Khan W, Chen E, MacManus M, Ray G, Lee K, Lamborn KR.
Blood.
1997;
90
(10):
4237-8
-
Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor.
Khan WB,
Shui C, Ning S, Knox SJ.
Radiat Res.
1997;
148
(3):
248-53
-
Influence of Bcl-2 overexpression on Na+/K(+)-ATPase pump activity: correlation with radiation-induced programmed cell death.
Gilbert M,
Knox S.
J Cell Physiol.
1997;
171
(3):
299-304
-
Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S,
Trisler K, Wessels BW, Knox SJ.
Cancer.
1997;
80
(12 Suppl):
2519-28
-
Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model.
Mac Manus M,
Lamborn K, Khan W, Varghese A, Graef L, Knox S.
Blood.
1997;
89
(7):
2303-10
-
Association of BCL-2 with membrane hyperpolarization and radioresistance.
Gilbert MS,
Saad AH, Rupnow BA, Knox SJ.
J Cell Physiol.
1996;
168
(1):
114-22
-
Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
Ning S,
Trisler K, Brown DM, Yu NY, Kanekal S, Lundsten MJ, Knox SJ.
Radiother Oncol.
1996;
39
(2):
179-89
-
Modulation of c-Myc activity and apoptosis in vivo.
Alarcon RM,
Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ.
Cancer Res.
1996;
56
(19):
4315-9
-
Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (Tirapazamine).
Gilbert MS,
Rupnow BA, Ramirez DA, Trisler KD, Knox SJ.
Cell Death Differ.
1996;
3
(2):
215-22
-
Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody.
Knox S,
Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C, Cornbleet PJ, Levy R.
Blood.
1996;
87
(3):
893-9
-
Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
Deb N,
Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C, Knox S.
Clin Cancer Res.
1996;
2
(8):
1289-97
-
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ,
Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-López A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R.
Clin Cancer Res.
1996;
2
(3):
457-70
-
Effects of stem cell factor on the growth and radiation survival of tumor cells.
Shui C,
Khan WB, Leigh BR, Turner AM, Wilder RB, Knox SJ.
Cancer Res.
1995;
55
(15):
3431-7
-
Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides.
Becker M,
Hoppe RT, Knox SJ.
Int J Radiat Oncol Biol Phys.
1995;
32
(5):
1445-9
-
Overview of studies on experimental radioimmunotherapy.
Knox SJ,
Cancer Res.
1995;
55
(23 Suppl):
5832s-5836s
-
Radioimmunotherapy of the Non-Hodgkin's Lymphomas.
Knox SJ,
Semin Radiat Oncol.
1995;
5
(4):
331-341
-
Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation.
Leigh BR,
Khan W, Hancock SL, Knox SJ.
Radiat Res.
1995;
142
(1):
12-5
-
Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy.
Knox SJ,
Fowler S, Marquez C, Hoppe RT.
Int J Radiat Oncol Biol Phys.
1994;
28
(2):
445-50
-
Organ modeling in the quantitation of planar images for distribution studies.
Goris ML,
Knox SA, Nielsen KR, Bouillant O.
Cancer.
1994;
73
(3 Suppl):
919-22
-
Stem cell factor enhances the survival of irradiated human bone marrow maintained in SCID mice.
Leigh BR,
Webb S, Hancock SL, Knox SJ.
Stem Cells.
1994;
12
(4):
430-5
-
The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts.
Wilder RB,
McGann JK, Sutherland WR, Waller EK, Minchinton AI, Goris ML, Knox SJ.
Int J Radiat Oncol Biol Phys.
1994;
28
(1):
119-26
-
Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry.
Langmuir VK,
Fowler JF, Knox SJ, Wessels BW, Sutherland RM, Wong JY.
Med Phys.
1993 Mar-Apr;
20
(2 Pt 2):
601-10
-
Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters.
Knox SJ,
Sutherland W, Goris ML.
Radiat Res.
1993;
135
(1):
24-31
-
Determinants of low dose rate effects associated with radioimmunotherapy.
Knox SJ,
Sutherland W, Goris ML.
Antibody Immunoconjugates and Radiopharmaceuticals.
1993:
6
197-207
-
Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
Wilder RB,
Langmuir VK, Mendonca HL, Goris ML, Knox SJ.
Cancer Res.
1993;
53
(13):
3022-7
-
Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment.
Knox SJ,
Goris ML, Wessels BW.
Radiotherapy Oncology.
1993:
25
219-220
-
The effect of stem cell factor on irradiated human bone marrow.
Leigh BR,
Hancock SL, Knox SJ.
Cancer Res.
1993;
53
(17):
3857-9
-
Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation.
Knox SJ,
Goris ML, Wessels BW.
Radiother Oncol.
1992;
23
(2):
111-7
-
The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotype mAb in murine B cell lymphoma.
Schiele J,
Knox SJ, Ruehl W, Goris ML.
Radiother Oncol.
1992;
24
(3):
169-76
-
Mycosis fungoides arthropathy.
Berger RG,
Knox SJ, Levy R, Sklar JL, Cohen P, Reichert T.
Ann Intern Med.
1991;
114
(7):
571-2
-
Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides.
Knox SJ,
Levy R, Hodgkinson S, Bell R, Brown S, Wood GS, Hoppe R, Abel EA, Steinman L, Berger RG.
Blood.
1991;
77
(1):
20-30
-
Results of the 1989 Association of Residents in Radiation Oncology survey.
Corn BW,
Taylor BW, Knox SJ, Martz KL, Flynn DF.
Int J Radiat Oncol Biol Phys.
1991;
20
(6):
1363-7
-
The biodistribution of 111In-anti-bFGF in a variety of tumors. Correlation with cell-binding assays.
Knox SJ,
Brown JM, McGann J, Sutherland W, Goris ML, Herblin WF, Gross JL.
Ann N Y Acad Sci.
1991:
638
497-502
-
Determinants of the antitumor effect of radiolabeled monoclonal antibodies.
Knox SJ,
Levy R, Miller RA, Uhland W, Schiele J, Ruehl W, Finston R, Day-Lollini P, Goris ML.
Cancer Res.
1990;
50
(16):
4935-40
-
The changing face of radiation oncology.
Meredith RF,
Halberg FE, Knox SJ.
South Med J.
1990;
83
(4):
488
-
Hyperthermia and radiation therapy in the treatment of recurrent Merkel cell tumors.
Knox SJ,
Kapp DS.
Cancer.
1988;
62
(8):
1479-86
-
Effect of thymopoietin and interleukin 2 on depressed mitogenic responsiveness and colony formation of lymphocytes from patients with preleukemia.
Knox SJ,
Rosenblatt LS, Anderson RW, Greenberg BR.
Thymus.
1986;
8
(1-2):
33-44
-
Two independent pathways of helper activity provided by a single T cell clone.
Shigeta M,
Takahara S, Knox SJ, Ishihara T, Vitetta ES, Fathman CG.
J Immunol.
1986;
136
(1):
34-8
-
Relation of age to lymphocyte radiosensitivity in vitro.
Knox SJ,
Shifrine M, Rosenblatt LS, Reeves JD, Woerner S.
Health Phys.
1984;
46
(2):
431-4
-
Lymphocyte abnormalities in preleukemia--I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors.
Anderson RW,
Volsky DJ, Greenberg B, Knox SJ, Bechtold T, Kuszynski C, Harada S, Purtilo DT.
Leuk Res.
1983;
7
(3):
389-95
-
Studies of T-lymphocytes in preleukemic disorders and acute nonlymphocytic leukemia: in vitro radiosensitivity, mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpopulations.
Knox SJ,
Greenberg BR, Anderson RW, Rosenblatt LS.
Blood.
1983;
61
(3):
449-55
-
Assessment of the in vitro radiosensitivity of human peripheral blood lymphocytes.
Knox SJ,
Shifrine M, Rosenblatt LS.
Radiat Res.
1982;
89
(3):
575-89
-
Growth of human T lymphocyte colonies from whole blood: culture requirements and applications.
Knox SJ,
Wilson FD, Greenberg BR, Shifrine M.
J Cell Biochem.
1982;
18
(1):
15-24
-
Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters.
Knox SJ,
Wilson FD, Miller CH, Rosenblatt LS, Shifrine M.
Stem Cells.
1982;
1
(6):
325-44
-
Radiation-induced inhibition of human lymphocyte blastogenesis: the effect of superoxide dismutase and catalase.
Knox SJ,
Misra HP, Shifrine M, Rosenblatt LS.
Int J Radiat Biol Relat Stud Phys Chem Med.
1982;
41
(3):
283-94
-
Cytogenetics and granulopoietic effects of bone marrow fibroblastic cells in Fanconi's anaemia.
Greenberg BR,
Wilson FD, Woo L, Knox S, Jenks H, Taplett J.
Br J Haematol.
1981;
48
(1):
85-93
-
Increased radiosensitivity of a subpopulation ot T-lymphocyte progenitors from patients with Fanconi's anemia.
Knox SJ,
Wilson FD, Greenberg BR, Shifrine M, Rosenblatt LS, Reeves JD, Misra H.
Blood.
1981;
57
(6):
1043-8
-
The selective growth of human T lymphocyte colonies from whole blood in a semisolid culture system.
Knox SJ,
Shifrine M, Wilson FD, Rosenblatt LS.
Exp Hematol.
1981;
9
(9):
926-37
-
A "whole-blood" technique for the quantitation of canine "T-lymphocyte" progenitors using a semisolid culture system.
Wilson FD,
Dyck JA, Knox SJ, Shifrine M.
Exp Hematol.
1980;
8
(8):
1031-9
-
Cell-mediated immunity in the dog in relation to disease: A review.
Knox SJ,
Shifrine M.
Comp Immun Microbiol Infect Dis.
1980:
2
405-415
-
Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents.
Hirsh DC,
Wiger N, Knox SJ.
Pharmacol Ther.
1979:
2
275-278
-
Pharmacokinetics of penicillin G in the turkey.
Hirsh DC,
Knox SJ, Conzelman GM, Wiger N.
Am J Vet Res.
1978;
39
(7):
1219-21
Navigation for This Section: GCRC
Find a Researcher
Help